It is worth mentioning that Qingchun Zhao's research group used a research strategy of old drugs for new applications, and found that terfenadine can act as a small molecule inhibitor of ADAM17, and can inhibit the activity of the ADAM17/Notch pathway in NSCLC cells, ultimately overcoming NSCLC cells resistance and improve sensitivity to oncology drugs 26,37,66-69. Here, ADAM17 is linked to non-small cell lung carcinoma.